Next Article in Journal
Administration of Bacterial Lipopolysaccharide during Early Postnatal Ontogenesis Induces Transient Impairment of Long-Term Synaptic Plasticity Associated with Behavioral Abnormalities in Young Rats
Next Article in Special Issue
Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses
Previous Article in Journal
Products Derived from Buchenavia tetraphylla Leaves Have In Vitro Antioxidant Activity and Protect Tenebrio molitor Larvae against Escherichia coli-Induced Injury
Previous Article in Special Issue
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I
Open AccessArticle

In Vitro Anti-Prostate Cancer Activity of Two Ebselen Analogues

1
Department of Bioenergetics and Physiology of Exercise, Medical University of Gdansk, 80-211 Gdansk, Poland
2
Department of Medical Biology and Genetics, University of Gdansk, 80-308 Gdansk, Poland
3
Department of Organic Chemistry, Faculty of Chemistry, Nicolaus Copernicus University, 87-100 Torun, Poland
4
Department of Life and Environmental Sciences, Polytechnic University of Marche, 60-100 Anconan, Italy
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(3), 47; https://doi.org/10.3390/ph13030047
Received: 28 February 2020 / Revised: 12 March 2020 / Accepted: 15 March 2020 / Published: 17 March 2020
(This article belongs to the Collection Old Pharmaceuticals with New Applications)
Scientific research has been underway for decades in order to develop an effective anticancer drug, and it has become crucial to find a novel and effective chemotherapeutics in the case of prostate cancer treatment. Ebselen derivatives have been shown to possess a variety of biological activities, including cytostatic and cytotoxic action against tumor cells. In this study, the cytotoxic effect and anticancer mechanism of action of two organoselenium compounds— (N-allyl-1,2-benzisoselenazol-3(2H)-one (N-allyl-BS) and N-(3-methylbutyl)-1,2-benzisoselenazol-3(2H)-one) (N-(3-mb)-BS)—were investigated on two phenotypically different prostate cancer cell lines DU 145 and PC-3. The influence of analyzed compounds on the viability parameter was also assessed on normal prostate cell line PNT1A. The results showed that both organoselenium compounds (OSCs) efficiently inhibited cancer cell proliferation, whereas normal PNT1A cells were less sensitive to the analazyed ebselen analouges. Both OSCs induced G2/M cell cycle arrest and prompted cell death through apoptosis. The detection of cleaved Poly (ADP-ribose) Polymerase (PARP) confirmed this. In addition, N-allyl-BS and N-(3-m)-b-BS increased the level of reactive oxygen species (ROS) formation, however only N-allyl-BS induced DNA damage. Based on our data, we assume that OSCs’ anticancer action can be associated with oxidative stress induction and inactivation of the Akt- dependent signalling pathway. In conclusion, our data demonstrate that ebselen derivatives showed strong cytotoxic efficiency towards prostate cancer cells and may be elucidated as a novel, potent anticancer agent. View Full-Text
Keywords: Organoselenium compound 1; apoptosis 2; ROS 3; DNA damage 4; chemoprevention 5 Organoselenium compound 1; apoptosis 2; ROS 3; DNA damage 4; chemoprevention 5
Show Figures

Figure 1

MDPI and ACS Style

Kaczor-Keller, K.B.; Pawlik, A.; Scianowski, J.; Pacuła, A.; Obieziurska, M.; Marcheggiani, F.; Cirilli, I.; Tiano, L.; Antosiewicz, J. In Vitro Anti-Prostate Cancer Activity of Two Ebselen Analogues. Pharmaceuticals 2020, 13, 47.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop